The Biochemistry of Chronic Pain and Fatigue

References

• LeResche L, Fricton J, Mohl N, et al. Research diagnostic criteria. Part II. J Cra-nio Dis Fac Oral Pain 1992; 6:327–334.
   Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatol-ogy 1990 criteria for the classification of fibromyalgia. Report of the multicenter cri-teria committee. Arthritis Rheum 1990; 33:160–172.
   PubMed Web of Science ®Google Scholar
• Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: A work-ing case definition. Ann Intern Med 1988; 108:387–389.
   PubMed Web of Science ®Google Scholar
• Sharpe MC, Archard LC, Banatvala JE, et al. A report-Chronic fatigue syn-drome: guidelines for research. J Roy Soc Med 1991; 84:118–121.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: A com-prehensive approach to its definition and study. Ann Intern Med 1994; 121:953–959.
   PubMed Web of Science ®Google Scholar
• Bombardier CH, Buchwald D. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia. Disability and health-care use. Med Care 1996; 34:924–930.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy indi-viduals. Am J Med 1996; 101:364–370.
   Google Scholar
• Flesh O, Wolfe F, Lane N. The relationship between fibromyalgia and tempo-romandibular disorders: prevalence and symptom severity. J Rheumatol 1996; 23: 1948–1952.
   Google Scholar
• Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness af-fecting Air Force veterans of the Gulf War. JAMA 1998; 280:981–988.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Buchwald DS. Chronic fatigue syndrome: an update. Ann Rev Med 1998; 49:1–13.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116:103–113.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A Synthetase/RNase L pathway associated with chronic fatigue syndrome. Guth Infect Dis 1994; 18:S96–S104.
   Web of Science ®Google Scholar
• Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 1997; 17:377–385.
   Google Scholar
• Bowles NE, Bayston TA, Zhang HY, et al. Persistence of enterovirus RNA in muscle biopsy samples suggests that some cases of chronic fatigue syndrome result from a previous, inflammatory viral myopathy. J Med 1993; 24:145–160.
   PubMedGoogle Scholar
• Galbraith DN, Nairn C, Clements GB. Phylogenetic analysis of short entero-viral sequences from patients with chronic fatigue syndrome. J Gen Virol 1995; 76:1701–1707.
   Google Scholar
• Manian FA. Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: is there evidence of activation of a nonspecific polyclonal immune response? Clin Infect Dis 1994; 19:448–453.
   PubMed Web of Science ®Google Scholar
• Gupta S, Vayuvegula B. A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immuno11991; 33:319–327.
   PubMed Web of Science ®Google Scholar
• Chao CC, Janoff EN, Hu SX, et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991; 3:292–298.
   PubMed Web of Science ®Google Scholar
• Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. (lin Infect Dis 1994; 18:S147–S153.
   Google Scholar
• Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997; 24:372–376.
   PubMed Web of Science ®Google Scholar
• De Meirleir K, Bisbal C, Campine I, et al. A 37Jda 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 1999; (in press).
   Google Scholar
• Lebleu B, Biscal C, Campine I, et al. A 37KDA 2-5A binding protein as a potential biochemical marker for the chronic fatigue syndrome. Proc 2nd World Con-gress on CFS and Related Disorders 1999; p. 54.
   Google Scholar
• Vojdani A, Choppa PC, Lapp CW. Down regulation of RNase L inhibitor cor-relates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome. J Clin Lab Immu-nol 1998; 50:1–16.
   Google Scholar
• Vojdani A, Lapp CW. Interferon-induced proteins are elevated in blood sam-ples of patients with chemically or virally induced chronic fatigue syndrome. Immu-nopharm Immunotox 1999; 21:175–202.
   PubMed Web of Science ®Google Scholar
• Baglioni C, Maroney PA, West DK. 2i,5i Olgio(A) polymerase activity and inhibition of viral RNA synthesis in interferon-treated HeLa cells. Biochemistry 1979; 18:1765–1770.
   Google Scholar
• Chebath J, Benech P, Revel M, Vigneron M. Constitutive expression of (2i-5i) oligio A synthetase confers resistance to picocornavirus infection. Nature 1987; 330:587–588.
   PubMed Web of Science ®Google Scholar
• Grun J, Kroon E, Zoller B, Krempien U, Jungwirth C. Reduced steady-state levels of vaccinia virus-specific early mRNAs in interferon-treated chick embryo fi-broblasts. Virology 1987; 158:28–33.
   Google Scholar
• De Benedetti A, Pytel BA, Baglioni C. Loss of (2'-5') oligioadenylate synthe-tase activity by production of antisense RNA results in lack of protection by interfer-on from viral infections. Proc Nat Acad Sci USA 1987; 84:658–662.
   Google Scholar
• McNair AN, Cheng D, Monjardino J, Thomas HC, Kerr IM. Hepatitis delta virus replication in vitro is not effected by interferon-alpha or-gamma despite intact cellular responses to interferon and dsRNA. J Gen Virol 1994; 75:1371–1378.
   Google Scholar
• Taylor JL, Will PL, Irizarry A, Tom P, O'Brien WJ. 2 i,5 i Oligioadenylate syn-thetase in interferon-alpha and acyclovir-treated herpes simplex virus-infected cells. J Interferon Cytokine Res 1995; 15:27–30.
   Google Scholar
• Sharp TV, Raine DA, Gewert DR, Joshi B, Jagus R, Clemens MJ. Activation of the interferon-inducible (2i-5i) oligoadenylate synthetase by the Epstein-Barr vi-rus RNA, EBER-1. Virology 1999; 257:303–313.
   PubMed Web of Science ®Google Scholar
• Metcalf LN, Roberts TK, McGregor NR, Dunstan RH, Butt HL. RNase-L, soluble IL-2 receptor and IL-6 levels in patients with chronic fatigue syndrome. Ho-nours Thesis, University of Newcastle, Australia.
   Google Scholar
• Allen-Mersh TG, Glover C, Fordy C, Henderson DC, Davies M. Relation be-tween depression and circulating immune products in patients with advanced colo-rectal cancer. J Roy Soc Med 1998; 91:408–413.
   Google Scholar
• Cleare AJ, Beam J, Allain T, et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Dis 1995; 35:283–289.
   Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatol 1997; 26:112S–121S.
   Google Scholar
• Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cog-nitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25:39–47.
   Google Scholar
• Noisakran S, Carr DJ. Lymphocytes delay kinetics of HSV-1 reactivation from in vitro explants of latent infected trigeminal ganglia. J Neuroimmunol 1999; 95:126–135.
   PubMed Web of Science ®Google Scholar
• Niblett S, Hoskin L, Clifton Bligh P, et al. Haematological and urinary amino and organic acid excretion in a cohort of patients with defined chronic fatigue syn-drome. Clinical Science, (Submitted for publication).
   Google Scholar
• Burnett RB, Chatterton BE, Gaffney RD, Scroop GC. Total body potassium concentration in chronic fatigue syndrome. Proc Int Conference The clinical and scientific basis of chronic fatigue syndrome: from myth toward management. 1998; pp. 31–35.
   Google Scholar
• Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HI— Blood pa-rameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. (submitted for publication).
   Google Scholar
• Rowe PC, Calkins H. Neurally mediated hypotension and chronic fatigue syn-drome. Am J Med 1998; 105:15S–21S.
   Google Scholar
• Bell DS. Vasopressin, circulating blood volume and the chronic fatigue syn-drome. Proc Int Conference The clinical and scientific basis of chronic fatigue syn-drome: from myth toward management. 1998; pp.131–138.
   Google Scholar
• Jeevanandam M. Trauma and sepsis. In Amino acid metabolism and therapy in health and nutritional disease. Ed Cynober LA. 1995, CRC Press, New York, pp. 245–255.
   Google Scholar
• Bachmann S. Mundel P. Nitric oxide in the kidney: synthesis, localization, and function. Am J Kidney Dis 1994; 24:112–129.
   Google Scholar
• Haynes WG, Hand MF, Dockrell ME, et al. Physiological role of nitric oxide in regulation of renal function in humans. Am J Physiol 1997; 272:F364–F371.
   PubMed Web of Science ®Google Scholar
• McGregor NR, Dunstan RH, Niblett S, et al. The effect of pain severity on metabolic homeostasis in chronic temporomandibular dysfunction type la (myofas-cial) pain patients. Manuscript in preparation.
   Google Scholar
• McGregor NR, Dunstan RH, Niblett S, et al. The effect of illness duration on metabolic homeostasis in chronic temporomandibular dysfunction type la (myofas-cial) pain patients. Manuscript in preparation.
   Google Scholar
• Mortimore GE, Poso AR. Intracellular protein catabolism and its control dur-ing nutrient deprivation and supply. Annu Rev Nutr 1987; 7:539–564.
   PubMed Web of Science ®Google Scholar
• Coderre TJ. The role of excitatory amino acid receptors and intracellular mes-sengers in persistent nociception after tissue injury in rats. Mol Neurobiol 1993; 7:229–246.
   PubMed Web of Science ®Google Scholar
• Coderre TJ, Yashpal K. Intracellular messengers contributing to persistent no-ciception and hyperalgesia induced by L-glutamate and substance P in the rat forma-lin pain model. Euro J Neurosci 1994; 6:1328–1334.
   PubMed Web of Science ®Google Scholar
• Hasselgren PO. Counter-regulatory hormones and the role of cytokines in the control of amino acid metabolism. Chapter 9 In Amino acid metabolism and therapy in health and nutritional disease. 1995; pp.139–156. CRC Press Inc. New York.
   Google Scholar
• Pullinger AG, Seligman DA, Solberg WK. Temporomandibular disorders. Part I: Functional status, dentomorphological features, and sex differences in a non-patient population. J Pros Dent 1988; 59:228–235.
   Google Scholar
• Kleinknecht PA, Alexander LD, Mahony ER, Dworkin SF. Correspondence between subjective report of temporomandibular disorder symptoms and clinical findings. JADA 1986; 113:257–261.
   PubMed Web of Science ®Google Scholar
• McGregor NR, Butt HE Zerbes M, Dunstan RH, Roberts TK, Klineberg IJ. As-sessment of pain (distribution & onset), symptoms, SCL-90-R inventory responses and the association with infectious events in patients with chronic orofacial pain. J Orofa-cial Pain. 1996; 10:339–350.
   PubMedGoogle Scholar
• Butt HL, Dunstan RH, McGregor NR, Roberts TK, Zerbes M, Klineberg IJ. An association of membrane damaging toxins from coagulase-negative staphylococ-cus and chronic orofacial muscle pain. J Med Microbiol 1998; 47:577–584.
   PubMed Web of Science ®Google Scholar
• McGregor NR, Dunstan RH, Butt HL, et al. Coagulase-negative staphylococ-cal membrane damaging toxins are associated with pain-related metabolic changes in chronic research diagnostic criteria type la muscle pain patients. submitted for publi-cation.
   Google Scholar
• Metcalf LN, McGregor NR, Roberts TK, Dunstan RH, Butt HL, Klineberg U. Membrane damaging toxins from coagulase-negative staphylococcus are associated with temporomandibular dysfunction (TMD) in patients with chronic fatigue syn-drome. Submitted for publication.
   Google Scholar
• Ghodratnama F, Riggio MP, Wray D. Search for human herpesvirus 6, human cytomegalovirus and varicella zoster virus DNA in recurrent aphthous stomatitis tis-sue. J Oral Path Med 1997; 26:192–197.
   Google Scholar
• Choppa PC, Vojdani A, Tagle C, Andrin R, Magtoto L. Multiplex PCR for the detection of Mycoplasma fermentans, M. hominis and M. penetrans in cell cultures and blood samples of patients with chronic fatigue syndrome. Molec Cell Probes 1998; 12:301–308.
   Google Scholar
• Lapp CW, Voyles CS, Davis P, Langford RN. Ampligen and chronic fatigue syndrome. Proc Int Conference The clinical and scientific basis of chronic fatigue syndrome: from myth toward management. 1998; pp. 26–30.
   Google Scholar
• Player MR, Torrence PF. The 2-5A System: Modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 1998; 78:55–113.
   PubMed Web of Science ®Google Scholar
• Wilder RL. Neuroendocrine-immune interactions and autoimmunity. Ann Rev Immunol 1995; 13:307–338.
   PubMed Web of Science ®Google Scholar